Daiichi Sankyo Pharmaceutical (Shanghai) Co. Ltd.

Main purpose of the study: To study the pharmacokinetic characteristics of the test preparation pravastatin sodium tablets (specification: 40 mg, produced by Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd.) and the reference preparation pravastatin sodium tablets (PRAREDUCT®, specification: 40 mg; produced by Daiichi Sankyo Europe GmbH) in healthy participants after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary purpose of the study: To study the safety of the test preparation pravastatin sodium tablets (specification: 40 mg) and the reference preparation pravastatin sodium tablets (PRAREDUCT®) (specification: 40 mg) in healthy participants

To evaluate the efficacy and safety of CS8663 20/5 mg in the treatment of primary mild to moderate hypertension in Chinese patients using 24-hour ABPM monitoring.